Patients' experiences of long-acting injectable antipsychotics: a qualitative study

被引:5
|
作者
Chiu, Lin-Ling [1 ]
Liu, Chun-Hao [2 ,3 ]
Chu, Chun-Lin [4 ]
Lin, Huang-Li [2 ]
Lii, Shu-Chung [5 ]
机构
[1] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp Linkou, Dept Psychiat, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp Linkou, Dept Child Psychiat, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp Taoyuan, Dept Psychiat, Taoyuan, Taiwan
[5] Chang Gung Univ, Coll Med, Humanist & Social Med Div, 259 Wen Hua 1st Rd, Taoyuan 333, Taiwan
关键词
antipsychotics; experience; long-acting injectable; LAI; qualitative research; SCHIZOPHRENIA; INJECTIONS; PROGRAM;
D O I
10.2147/NDT.S206154
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: In this study, we applied a qualitative approach to explore patients' subjective experiences of long-acting injectable antipsychotics (LAIs). Methods: Patients undergoing psychiatric treatment from the chronic ward or outpatient department of a medical center in northern Taiwan who had experience with LAI treatment were enrolled. Information was obtained through semi-structured in-depth interviews. The interviews were audio-recorded and then translated verbatim, and the data were collected and analyzed concurrently to develop major themes and categories. Result: In total, 14 participants (8 female) were interviewed. In a bio-psycho-social model, the participants used LAIs as a method to become "normal," in order to achieve a balance between the "effects" and "side effects" that may influence their daily lives. Their past experiences constructed their concepts about and expectations regarding LAIs, and their relationships with their family members and co-workers also modeled their experiences. Conclusion: In our study, we sought to understand the experience of LAI in the daily life context of the patients. We attempted to use a bio-psycho-social model to evaluate the subjective experience of the patients; an improved understanding can help mental health specialists gain a closer insight into patient experience.
引用
收藏
页码:1797 / 1804
页数:8
相关论文
共 50 条
  • [41] Long-acting injectable antipsychotics: what, when, and how
    Citrome, Leslie
    CNS SPECTRUMS, 2021, 26 (02) : 118 - 129
  • [42] LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN FIRST EPISODE SCHIZOPHRENIA
    Fleischhacker, Wolfgang
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S312 - S312
  • [43] Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update
    Mohr, Pavel
    Volavka, Jan
    DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, 2012, 25 (04): : 285 - 296
  • [44] Long-acting injectable antipsychotics during pregnancy: An update
    Paraschakis, A.
    Papasaika, M.
    EUROPEAN PSYCHIATRY, 2021, 64 : S834 - S835
  • [45] Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
    Manchanda, Rahul
    Chue, Pierre
    Malla, Ashok
    Tibbo, Phil
    Roy, Marc-Andre
    Williams, Richard
    Iyer, Srividya
    Lutgens, Danyael
    Banks, Nicola
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (05): : 5S - 13S
  • [46] Long-acting injectable antipsychotics: shall the last be first?
    Stahl, Stephen M.
    CNS SPECTRUMS, 2014, 19 (01) : 3 - 5
  • [47] Long-acting injectable versus oral antipsychotics for schizophrenia
    Munkholm, Klaus
    LANCET PSYCHIATRY, 2021, 8 (07): : 566 - 567
  • [48] The place of long-acting injectable antipsychotics in the treatment of schizophrenia
    Kane, John M.
    Rubio, Jose M.
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [49] Long-acting injectable antipsychotics: focus on olanzapine pamoate
    Lindenmayer, J. P.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 261 - 267
  • [50] Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder
    Parikh, Parinda
    Sood, Kanuja
    Bansal, Lajpat Rai
    Abraham, Jeby
    Eichbaum, Anjali
    Shoda, Enfu Keith
    Buddhavarapu, Mahiya
    Oza, Mina
    Chandra, Arushi Parikh
    Simanowitz, Channa
    Witriol, Martin
    Nasrallah, Henry
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2025, 35 (02) : 92 - 98